(1) Lannett Co., Inc. (NYSE:LCI) triggered: 11/18/2019
Lannett Company develops, manufactures, packages, markets, and distributes solid oral and extended release (tablets and capsules), topical, liquids, nasal and oral solution finished dosage forms of drugs, generic forms of both small molecule and biologic medications, that address various therapeutic areas. Co.'s products are: Levothyroxine Sodium tablets, which are used for the treatment of thyroid deficiency; Fluphenazine tablets, which are used for the management of manifestations of psychotic disorders; Verapamil SR tablets, which are used in the treatment of high blood pressure, arrhythmia and angina; and Ursodiol Capsules, which are used for the treatment and prevention of gallstones.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.